thenewsfacts.com
  • Home
  • Latest News
  • Trending News
  • Entertainment
  • Technology
  • Sports
  • Business
  • Health
thenewsfacts.comthenewsfacts.com
Font ResizerAa
Search
  • Home
  • Latest News
  • Trending News
  • Entertainment
  • Technology
  • Sports
  • Business
  • Health
Follow US
© thenewsfacts : All Rights Reserved.

Home » Bharat Biotech firmly condemns baseless reports on COVAXIN Development

Latest News

Bharat Biotech firmly condemns baseless reports on COVAXIN Development

TheNewsFacts
Last updated: November 17, 2022 1:13 pm
TheNewsFacts
Share
Bharat Biotech firmly condemns baseless reports on COVAXIN Development
SHARE

Bharat Biotech today strongly condemned fallacious and misleading information report recently by a foreign media.

The company in a statement said -We condemn the targeted narrative against COVAXIN put forth by a select few individuals and groups who have no expertise in vaccines or vaccinology. It is well known that they helped perpetuate misinformation and fake news throughout the pandemic. They are unable to comprehend global product development and licensure processes. 

The Ministry of Health, Government of India also issued a statement and wrote:

Media Reports claiming regulatory approval for Covaxin was rushed due to Political Pressure are Misleading and Fallacious

Scientific approach and prescribed norms adhered to in approving Covid-19 vaccines for Emergency Use Authorization

There have been media reports claiming that Bharat Biotech, manufacturer of the indigenous COVID-19 vaccine – Covaxin, “had to skip certain processes” and “speed” up clinical trials due to political pressure. The reports further claim that there were several irregularities in the three phases of the clinical trials conducted for the vaccine. These media reports are completely misleading, fallacious and ill-informed.

It is clarified that Government of India and the national regulator i.e. CDSCO have followed a scientific approach and prescribed norms in approving COVID-19 vaccines for emergency use authorization. The Subject Expert Committee (SEC) of Central Drugs Standard Control Organisation (CDSCO) met on 1st and 2nd January, 2021 and after due deliberations made recommendations in respect of proposal for Restricted Emergency Approval of COVID-19 virus vaccine of Bharat Biotech.

There was no external pressure to accelerate development of COVAXIN – Bharat Biotech

The pressure was all internal to develop a safe, and effective vaccine for the Covid-19 pandemic, to save lives and livelihoods in India and Globally. 

COVAXIN is one of the most highly studied covid-19 vaccines worldwide. COVAXIN was evaluated in ~20 pre-clinical studies, including 3 challenge trials and 9 human clinical studies, more than any other Indian Covid-19 vaccine. These trials have clearly demonstrated safety and efficacy of COVAXIN. 

With several hundred million doses administered worldwide, COVAXIN has demonstrated an excellent safety record with minimal adverse events and no vaccine associated cases detected for myocarditis or thrombocytopenia. 

The entire product development and clinical studies were executed as per global guidelines and submitted worldwide. Data from COVAXIN has resulted in more than 20 publications, documenting every aspect its development.  

The recent media reports around the approvals for COVAXIN are incorrect and erroneous. These few individuals and organizations were mostly involved in fake news and false information during the pandemic. They fail to understand product development and licensure pathways worldwide. 

The phase I study for COVAXIN was one of the largest in the world, resulting in both the 3 and 6 mcg doses demonstrating safety and comparable immunogenicity. The decision to proceed to phase III trials was taken based on data from phase I studies and results from successful animal challenge trials.

The phase II studies were designed to determine if the lower dose of 3 mcg would be effective, instead of the 6 mcg dose, which would have doubled our manufacturing capacity. In the interest of public health, it was decided to proceed with the 6 mcg dose for phase III clinical trials.    

Vaccines against ebola and monkey pox, were approved by stringent regulatory agencies in developed countries based on phase I and II clinical data only and without phase III data. If such an approval was given by regulators in India, there would be an uproar, but the same people and organizations remain silent, demonstrating their hypocrisy.

While these people and organizations were busy with false information and fake news during the pandemic, more than 1000 personnel at Bharat Biotech across India were busy developing, testing, manufacturing and distributing COVAXIN.

Our diligent efforts have resulted in an universal Covid-19 vaccine for adults and children alike, which can be administered repeatedly as booster doses without safety concerns. The Bharat Biotech team is extremely proud of its efforts to develop a novel Covid-19 vaccine for India and the world.

These efforts to discredit our work will not deter us.

TAGGED: Bharat Biotech, BHARAT BIOTECH COVAXIN, Bharat Biotech refutes claims, Covaxin, Covaxin News
Share This Article
Twitter Email Copy Link Print
Previous Article Apple Watch Saves a 17-Year-Old After He Fell Into A Deep Gorge
Next Article Skyroot makes history today by launching India’s first private rocket Skyroot makes history today by launching India’s first private rocket

Your Trusted Source for Accurate and Timely Updates!

We're committed to providing accurate and unbiased news as it unfolds, earning the trust of a large audience. Stay informed with our news updates on the latest events and trends, keeping you ahead of the curve.
FacebookLike
TwitterFollow
InstagramFollow

Popular Posts

Big News of the day, India Overtakes US in Covid vaccination drive

A big boost to the world's #LargestVaccineDrive - India overtakes the USA in total number…

By TheNewsFacts

Dangal Zaira Wasim new Insta pic creates a big buzz

Zaira Wasim after disappearing from Bollywood 2 years ago, today shared her first picture on…

By TheNewsFacts

King Kohli Continues to Set New Epic Records at 35; A Big Knock in Waiting On His Birthday

King Kohli, the former India captain and one of the greatest batters of all time,…

By TheNewsFacts

You Might Also Like

Biovet Lumpy Skin Disease Vaccine Launched
Latest News

BIOLUMPIVAXIN: New Vaccine Now Available to Protect Livestock from LSD

By NewsFacts Bureau
Google AI First Accelerator 2025 India
Latest News

Google Opens 2025 India AI First Accelerator: $17B Opportunity for Startups

By NewsFacts Bureau
Salman Khan
Latest News

Bhai Salman in Hot Seat: Ceasefire Tweet Deleted After Fury

By NewsFacts Bureau
AM Green
Latest News

AM Green-CIL Strike ₹25,000 Cr Mega Renewable Energy Deal

By NewsFacts Bureau
thenewsfacts thenewsfacts

About US


TheNewsFacts: Brings you the interesting facts, news facts and updates from India an the world across politics, tech, entertainment, business, tending, and more. We deliver what you love to read.
Top Categories
  • Latest News
  • Trending News
  • Paris Olympics 2024
  • Sports
  • Entertainment
  • Business
  • Technology
Usefull Links
  • About The News Facts
  • Latest News
  • Privacy Policy
  • Editorial Policy
  • Disclaimer
  • Contact Us
Follow us
Facebook Twitter Instagram

© thenewsfacts. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?